internal
Kristin C. Peck
Chief Executive Officer
Executive
6 yr
23 reports
Zoetis Inc. ·ZTS
CEO runs enterprise without a COO layer
Health Care · Fortune #435 · Hybrid structure · 14K employees · Parsippany, New Jersey
View as of:
5
CEO span
↓ tighter than peers (avg 8)
2.3
Avg span
tight
3
Max depth
3 levels
4.4 yr
Avg tenure
stable vs FY2024
60%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$9.5B
Net income
$2.7B
Total assets
$15.5B
Shares out
422M
Sourced from Zoetis Inc. DEF 14A · filed 2026-04-08 ↗ View on SEC
Interactive org chart
Zoetis Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
CEO runs enterprise without a COO layer. This page maps Zoetis’ enterprise structure, executive team and reporting lines, highlights recent leadership transitions, and compares Zoetis’ lean top team with animal-health peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Robert J. Polzer departed as EVP and President, Research and Development
Retired effective December 31, 2025; transitioned to consultant role through 2026.
Source · See change logScenario views in the chart
- Add Chief Operating Officer Insert a COO between the CEO and operations/commercial leaders to reduce CEO span and centralize execution.
- Split U.S. and International Presidents Create separate U.S. and International presidents reporting to the CEO, reducing the CCO span but adding depth.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
6 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
Wetteny Joseph
Executive Vice President and Chief Financial Officer
Finance
5 yr
4 reports
Jamie Brannan
Executive Vice President and Chief Commercial Officer
Commercial
3 yr
4 reports
Open Role
President, Research and Development
R&D
1 yr
4 reports
internal
Roxanne Lagano
Executive Vice President, General Counsel and Corporate Secretary
Legal
7 yr
3 reports
Open Role
Chief Manufacturing & Supply Officer
Operations
2 yr
3 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 5 named executive officers disclosed. Bar length scales with total compensation.
Kristin C. Peck $19.0M
- Base salary
- $1.35M
- Stock awards
- $10.22M
- Option awards
- $3.41M
- Non-equity incentive
- $2.19M
- Other
- $1.88M
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Wetteny Joseph $5.6M
- Base salary
- $800K
- Stock awards
- $2.85M
- Option awards
- $950K
- Non-equity incentive
- $832K
- Other
- $165K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Jamie Brannan $4.0M
- Base salary
- $720K
- Stock awards
- $1.67M
- Option awards
- $558K
- Non-equity incentive
- $674K
- Other
- $349K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Robert J. Polzer $3.7M
- Base salary
- $710K
- Stock awards
- $1.67M
- Option awards
- $555K
- Non-equity incentive
- $591K
- Other
- $145K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
Roxanne Lagano $2.8M
- Base salary
- $700K
- Stock awards
- $1.04M
- Option awards
- $347K
- Non-equity incentive
- $605K
- Other
- $131K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The businesses
How Zoetis Inc. divides the work
4 divisions report into the group CEO. Tile size scales with estimated headcount.
Commercial
5K employees
Chief Commercial Officer (Jamie Brannan)
Global sales, marketing and customer engagement across companion animal and livestock portfolios.
Research & Development
2K employees
President, Research and Development (Open Role)
Discovery, development and lifecycle management of medicines, vaccines and diagnostics.
Manufacturing & Supply
3K employees
Chief Manufacturing & Supply Officer (Open Role)
Global manufacturing, quality, EHS and supply chain operations.
Finance
800 employees
Chief Financial Officer (Wetteny Joseph)
Financial planning, reporting, treasury, tax and investor relations.
The thesis
Why this org is unusual
Zoetis is distinctive for operating without a Chief Operating Officer, with the CEO retaining direct oversight of commercial, R&D, legal, finance and supply leadership.
This creates a wide CEO span but keeps P&L ownership concentrated in commercial leadership rather than divisional presidents. The structure reflects Zoetis’ enterprise model with two reporting segments (U.S. and International) embedded under the Chief Commercial Officer rather than standalone segment CEOs.
- No COO role
- Commercial led by a single global CCO
- R&D president vacancy post-2025 retirement
The comparison
How Zoetis Inc. stacks up
Compared with animal-health peers, Zoetis’ structure is lean at the top and COO-less. Peers such as Elanco and IDEXX typically insert a COO or divisional presidents between the CEO and operations. Zoetis instead emphasizes functional depth in R&D and commercial execution, consistent with its innovation-led strategy …
C-suite size
Zoetis Inc.
6
Elanco
8
IDEXX Laboratories
7
Merck Animal Health
9
Boehringer Ingelheim AH
9
Reporting depth
Zoetis Inc.
3 levels
Elanco
4 levels
IDEXX Laboratories
4 levels
Merck Animal Health
5 levels
Boehringer Ingelheim AH
5 levels
Avg C-suite tenure
Zoetis Inc.
4 yr
Elanco
3 yr
IDEXX Laboratories
5 yr
Merck Animal Health
6 yr
Boehringer Ingelheim AH
7 yr
Has COO / Has CAIO
Zoetis Inc. — no COO — no CAIO
Elanco ✓ COO — no CAIO
IDEXX Laboratories — no COO — no CAIO
Merck Animal Health ✓ COO ✓ CAIO
Boehringer Ingelheim AH ✓ COO — no CAIO
Current signals
What changed recently
Most significant change was the retirement of R&D President Robert Polzer at year-end 2025.
- departedRobert J. Polzer EVP and President, Research and Development
Retired effective December 31, 2025; transitioned to consultant role through 2026.
Source - new
- new
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-04-08
- CEO
- Kristin C. Peck
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 4.4 yr
Year marked by R&D leadership transition.
Named executive officers (5)
- Kristin C. Peck - CEO since 2020
- Wetteny Joseph - CFO since 2020
- Jamie Brannan - Chief Commercial Officer since 2022
- Robert J. Polzer - President, R&D since 2019
- Roxanne Lagano - General Counsel since 2018
FY2024
DEF 14A filed 2025-04-09
- CEO
- Kristin C. Peck
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 4.1 yr
Stable enterprise leadership.
Named executive officers (5)
- Kristin C. Peck - CEO since 2020
- Wetteny Joseph - CFO since 2020
- Jamie Brannan - Chief Commercial Officer since 2022
- Robert J. Polzer - President, R&D since 2019
- Roxanne Lagano - General Counsel since 2018
FY2023
DEF 14A filed 2024-04-10
- CEO
- Kristin C. Peck
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 3.8 yr
Commercial leadership still bedding in.
Named executive officers (5)
- Kristin C. Peck - CEO since 2020
- Wetteny Joseph - CFO since 2020
- Jamie Brannan - Chief Commercial Officer since 2022
- Robert J. Polzer - President, R&D since 2019
- Roxanne Lagano - General Counsel since 2018
Year-over-year changes
Leadership team remained unchanged, with incremental tenure maturation.
- Avg tenure: 3.8 → 4.1 yr
R&D president retired at year-end 2025, creating a leadership vacancy.
- Avg tenure: 4.1 → 4.4 yr
- departed Robert J. Polzer - President, R&D (was President, R&D) (DEF 14A 2026-04-08)
The board
Board of directors
13 directors. 12 of 13 independent (92%). Source: most recent DEF 14A.
Kristin C. Peck
Inside
CEO, Zoetis
Paul M. Bisaro
Independent
Vanessa Broadhurst
Independent
Frank A. D'Amelio
Independent
Gavin D.K. Hattersley
Independent
Sanjay Khosla
Independent
Antoinette R. Leatherberry
Independent
Michael B. McCallister
Independent
Gregory Norden
Independent
Louise M. Parent
Independent
Willie M. Reed
Independent
Mark Stetter
Independent
Stephanie Tilenius
Independent
The board, organized
Board committees
4 standing committees. Audit and Compensation must be 100% independent under SEC rules; the rest vary.
Audit Committee
100% independent
Human Resources Committee
100% independent 5 mtgs/yr
- Sanjay Khosla
- Antoinette R. Leatherberry
- Mark Stetter
- Stephanie Tilenius
Corporate Governance Committee
100% independent
Quality and Innovation Committee
100% independent 5 mtgs/yr
- Paul M. Bisaro
- Vanessa Broadhurst
- Sanjay Khosla
- Mark Stetter
Frequently Asked Questions
Who is the CEO of Zoetis?
Kristin C. Peck has served as CEO of Zoetis since 2020.
What type of organizational structure does Zoetis use?
Zoetis uses a hybrid enterprise structure with strong functional leadership and embedded geographic segments.
How many direct reports does Zoetis's CEO have?
The CEO has five direct reports across finance, commercial, legal, R&D and operations.
How has Zoetis's leadership changed recently?
In late 2025, R&D President Robert Polzer retired, and the Board added directors Mark Stetter and Stephanie Tilenius.
Does Zoetis have a COO?
No. Zoetis operates without a Chief Operating Officer, with major functions reporting directly to the CEO.
Sources
- DEF 14A filed Apr 8, 2026
- Form 8-K filed Oct 28, 2025
- Form 8-K filed May 22, 2025
- SEC EDGAR: Zoetis Inc. DEF 14A Proxy Statement
- SEC EDGAR: Zoetis Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Zoetis Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/zoetis/MLA 9th
"Zoetis Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/zoetis/. Accessed .Chicago 17
Creately. "Zoetis Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/zoetis/.Original SEC source View on SEC ↗
Zoetis Inc.. DEF 14A. Filed 2026-04-08. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1555280/000155528026000015/zts-20260406.htmPermanent URL: https://creately.com/org-chart/fortune-500/zoetis/ · last updated 2026-04-01